AC Immune Ltd
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 98.9% | 2,207.4% | 2,494.6% | 56.8% | – | – | – | – | – | – | – | – | |
| – | 100.0% | -2,207.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 98.9% | 2,207.4% | 2,494.6% | 56.8% | 1,388.3% | 1,607.7% | 1,288.4% | 1,392.0% | 3,119.0% | 1,049.5% | 69.3% | 261.8% | |
| – | 4.6% | 723.6% | 662.4% | 14.7% | 161.9% | 448.8% | 298.3% | 379.9% | 75.1% | 373.0% | 23.4% | 65.9% | |
| – | 123.9% | 2,921.1% | 3,151.1% | 71.5% | 1,737.5% | 2,056.6% | 1,584.5% | 1,821.6% | 4,362.1% | 1,421.5% | 92.1% | 352.3% | |
| – | -23.9% | -2,921.1% | -3,051.1% | 28.5% | -1,637.5% | -1,956.6% | -1,484.5% | -1,721.6% | -4,262.1% | -1,321.5% | 7.9% | -252.3% | |
| – | 0.2% | 5.2% | 4.9% | 0.1% | 2.6% | 5.5% | 3.8% | 4.9% | 12.3% | 5.8% | 0.4% | 1.2% | |
| – | -32.0% | -2,600.0% | -3,313.0% | 21.6% | -1,389.1% | -1,922.1% | -1,622.4% | -1,688.8% | -4,252.4% | -1,322.7% | 12.4% | -246.5% | |
| – | 0.0% | 5.2% | – | – | 0.3% | – | – | – | – | – | – | – | |
| – | -32.1% | -2,600.0% | -3,313.0% | 21.6% | -1,389.4% | -1,922.1% | -1,622.4% | -1,688.8% | -4,252.4% | -1,322.7% | 12.4% | -246.5% | |
| – | -28.1% | -2,513.8% | -3,228.2% | 23.8% | -1,339.9% | -1,854.8% | -1,570.9% | -1,652.6% | -4,046.2% | -1,316.9% | 12.8% | -239.8% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.